Cellmedi List of treatments
A.stem cell-pneumoconiosis
Stem cells can effectively repair pneumoconiosis damage caused by haze
• Haze impacts the cardiovascular, cerebrovascular, and nervous systems, with the respiratory system being the first to bear the brunt.
• In Beijing, Lung cancer cases have increased by 60% in the past 10 years.
• Stem cells can effectively repair lung epithelial damage and eliminate chronic inflammation caused by haze particles, thereby lowering lung cancer risk factors (chronic inflammation leading to tumorigenesis).
A.stem cell-Ovarian function recovery
Use scenarios for ovarian specialized stem cells
• Premature ovarian failure
• Disturbance of estrogen secretion
• Insufficient number of follicles for IVF
• Ovarian damage after surgery or chemoradiotherapy
• Thin uterus or chocolate cysts
• Ovarian maintenance
How to use ovarian specific stem cells
A.stem cell-Cartilage damage disease
Current status of cartilage damage disease
355 million people worldwide suffer from arthritis
Cartilage is a dense connective tissue without blood vessels, and once damaged, it cannot heal on its own.
Stem cell therapy for arthritis
Practical examples
MRI comparison before and after intervention
A. Stem Cell – Skin anti-aging
Anti-aging, face(Exosomes)
Skin anti-aging stem cells
Skin anti-aging treatments are mainly composed of stem cells + cell exosomes, which deeply repair skin cells and addresses various skin problems.
How to use skin anti-aging stem cells
Acne marks, acne pits, inflammation of the skinAnti-aging, face(Exosomes)
Regeneration and lifting
Cellmedi List of treatments
❉.Lung Cancer 131 cases + Gastrointestinal Tumors 114 cases + Colon Cancer 41 cases + Pancreatic Cancer 21 cases + Renal Cancer 42 cases + Liver Cancer 24 cases + Malignant Melanoma 10 cases + Ovarian Cancer 15 cases + Cervical Cancer 15 cases + Breast Cancer 26 cases + Penile/Bladder/Prostate Cancer 27 cases + Gallbladder/Bile Duct Cancer 19 cases + Head and Neck Tumors 14 cases + Lymphoma 16 cases + Sarcoma 17 cases + Nasopharyngeal Cancer 2 cases
Research big data
Study on the Japanese Cancer-prone Population—Multi-year Follow-up Study
Effect of NK treatment in patients with large B lymphoma
NK cell therapy for lung cancer patients
• Ms. Liu’s was diagnosed with lung cancer measuring 4.3×3.2cm. After undergoing minimally invasive surgical resection and four cycles of chemotherapy (pemetrexed + oxaliplatin), a new nodule was detected two years later. This nodule grew rapidly from 1cm to 5.5×5.5x3cm in a short period. A biopsy confirmed tumor recurrence after surgery. Due to the rapid growth, high degree of malignancy, and its location near the aorta in the right lung, a second operation is very difficult.
•Below are the results of the case section
Eight courses of radiographs were taken after the examination results
From February 2016 to September 23, 2017, imaging results showed a flaky shadow approximately 0.2 x 0.2cm in the upper lobe of the left lung. The size remained stable, and observation was recommended. No shifts in the 12-1 lymph nodes were noted.
There was no obvious invasion of solid organs, no bony destruction, and no abnormal signs in the surgical area.
Immune cell therapy for kidney cancer patients
Name: Yan XX male
Clinical diagnosis: Renal CA
Three courses of immunotherapy each consisting of
four treatments over four consecutive days.
Cell types used: NK and CIK
By the end of December 18 and February 19, physical
examination results showed improvement compared
to before treatment.
Wang: Director of a department at the Second People’s Hospital of Taiyuan City Disease: Pancreatic cancer
In March 2018, Mr. Wang was diagnosed with pancreatic cancer at the General Hospital of the Chinese People’s Liberation Army and was discharged after treatment.
He underwent CIK immunobiological therapy and adjuvant therapy in May, June and July. As a result, his tumor marker CA19-9 index decreased from 192 to 34, returning to normal levels. Following chemotherapy and radiotherapy, Mr. Wang reported significant improvement, including elimination of discomfort, hair regrowth, abundant energy, normalized diet and sleep, and weight increase from 63kg to 66kg.
His condition and quality of life have improved significantly.
Kidney regeneration
Ms. Lu, 57 years old, was diagnosed with nephritis and atrophy of
both kidneys at the First Hospital of Shandong University
After a long treatment process, he had no choice but to consider a
kidney replacement, but no donor was available.
The two kidneys have increased in size compared to the previous
atrophy of 2 cm.
The left kidney has grown by 1 cm, and the right kidney has grown
by 0.8 cm (based on the examination results from the 301
Hospital).
Urine protein levels have improved from 3+ to now weakly positive.
Hepatitis B, cirrhosis
Case 5: Hepatitis B, cirrhosis
Wang XX, 54 years old, from Qujing, Yunnan, was diagnosed with
hepatitis B and liver cirrhosis in 2018 and received treatment at
Beijing 302 Hospital.
After two cycles of stem cell therapy, liver function has recovered,
and liver stiffness has improved significantly.
GP96 Disease List
| TP-129-Enhancing anti-tumor immunity in healthy people | TK-129- Reducing the risk of cancer recurrence in patients | TB-39-Improving or eliminating autoimmune diseases |
| 1.1 Thyroid Autoimmune Diseases | 2.Cancer-Related | 3.1 Digestive System Diseases |
| Hyperthyroidism | Abnormal Tumor Markers | Hepatitis B |
| Thyroid Nodules | Lung Cancer (NSCLC) | Hepatitis C |
| Prostate Cancer | Liver Cirrhosis | |
| Thyroid Cancer | Crohn’s Disease | |
| Cervical Cancer | Chronic Hepatitis B | |
| 1.2 Suboptimal Health Conditions | Breast Cancer | 3.2 Autoimmune Diseases |
| Low Energy | Esophageal Squamous Cell Carcinoma | Systemic Lupus Erythematosus |
| Immunodeficiency | Esophageal Cancer | Rheumatoid Arthritis |
| Nodules, Polyps, Cysts, Fibroids, LipomasExamples: Breast Nodules, Lung Nodules, Liver Cysts, Polyps, Uterine Fibroids, Renal Fibroids, Fatty Tumors | Hepatocellular Carcinoma | Systemic Sclerosis |
| Chronic Inflammation | Pancreatic Cancer | Vitiligo |
| Lymph Node Enlargement | Glioma (Brain Tumor) | Scleroderma |
| Breast Cysts | Hashimoto’s Disease | |
| Psoriasis | ||
| Erythroderma | ||
| Henoch-Schönlein Purpura (HSP) | ||
| Sjogren’s Syndrome | ||
| Myasthenia Gravis | ||
| Eczema | ||
| Autoimmune Hepatitis | ||
| Multiple Sclerosis | ||
| Allergic Asthma | ||
| Allergic Rhinitis | ||
| Neuromyelitis Optica | ||
| Amyotrophic Lateral Sclerosis (ALS) | ||
| Irritable Bowel Syndrome (IBS) |
Treatment projects
TP-129-Enhancing anti-tumor immunity in healthy people
TK-129-Reducing the risk of cancer recurrence in patients
TB-39-Improving or eliminating autoimmune diseases
Case Study
7.1 TP-129 Case Study 1
7.2 TP-129 Case Study 2
7.3 TP-129 Case Study 3
Mr. Zhao, 36 years old, has had chronic hepatitis B with positive HBeAg for over 20 years. In February 2018, he underwent TP-129 immunotherapy. After five sessions of treatment, follow-up tests in July 2019 showed that his HBeAg status changed from positive (large three positives) to negative (small three positives). His condition has remained stable during follow-up visits to date.
7.4 TP-129 Case Study 4
Ms. Li, 47 years old, had been infected with HPV for over 10 years and had tried various treatments without success. In December 2018, a follow-up test revealed positive results for HPV types 16, 56, and 59. In January 2019, she began receiving TP-129 in combination with PD-1 immunotherapy. After completing her 10th session in May 2019, a follow-up test showed that all HPV subtypes had turned negative. However, since her spouse did not receive simultaneous immunotherapy, a follow-up in August revealed that types 33 and 56 had turned positive again. In November, she began receiving TP-129 in combination with the HPV nine-valent vaccine. After the fourth immunotherapy session, a follow-up showed that HPV type 56 had turned negative.
TK-129-Reducing the risk of cancer recurrence in patients
7.5 TK-129 Case Study 1
Mr. Zhu, 71 years old, was diagnosed with invasive adenocarcinoma of the lung with brain metastasis, following surgery more than six months ago. Post-surgery, he received chemotherapy and radiotherapy without any additional treatments. He occasionally experienced symptoms such as headaches, dizziness, and drowsiness. On August 26, 2019, he began TK-129 immunotherapy. A follow-up brain CT scan two months later (October 28) showed a significant reduction in the metastatic lesions compared to before, and his symptoms of headaches, dizziness, and drowsiness were notably alleviated. His condition remained stable during the six-month follow-up period.
7.5 TK-129 Case Study 2
Mr. Liu, 57 years old, had central lung cancer in the right lower lung for more than four years, with multiple metastases in lungs, brain and thoracic lumbar spine. The pathological classification is adenocarcinoma and he did not receive surgical treatment. During this period, he received chemotherapy, cellular immunotherapy and targeted drug treatment, but his condition was not effectively controlled. On March 18, 2019, following the application of targeted drugs, he began combined treatment with TK-129 immunotherapy. A re-examination on May 8 showed that the extent of the central lung cancer in the right lower lung had shrunk compared to before. After one year of follow-up, his condition was under stable control.
7.5 TK-129 Case Study3
Ms. Tao, 46 years old, postoperative thyroid cancer.
- Thyroid enlargement was detected during the thyroid surgery in June 2019. She was diagnosed with papillary thyroid cancer, which was subsequently removed.
- Before receiving TK-129 immunization, a physical examination revealed that the patient’s tumor-associated antigen 12-5 index was abnormal.
- On August 7, 2021, she received TK-129 + mg/time PD-1 antibody (K drug). Prior to the first immunization, she was intravenously infused with 400 mg of cyclophosphamide. The final immunization was completed on October 9, 2021, for a total of ten sessions.
7.6 TK-129 Case Study4
Ms. Luo, 71 years old, breast cancer
1. After surgery and before heat shock protein inoculation, ultrasound results showed:
1) A band-like low echo on the right chest wall, suggestive of local effusion.
2) Enlargement of left supraclavicular lymph nodes.
2. After one course of heat shock protein immunization and a follow-up for half a year, both the effusion and hypertrophic lymph nodes had disappeared.
Comparison before and after immunization:
TB-39-Improving or eliminating autoimmune diseases
TK-129 Case Study 1
Ms. Xiao, 64 years old, had erythroderma that recurred for more than two years. The patient exhibited diffuse flushing of the skin all over the body,, with cracked and desquamated skin on the neck, accompanied by mild swelling. The treatment effect at the local hospital was not satisfactory.
On March 8, 2019, she received TB-39 immunization. After the third immunization (April 8), the skin flushing had subsided, and the neck skin returned to normal. She continued to receive immunization until the end of the treatment course. However, follow-up after one year showed a recurrence of her condition.
TK-129 Case Study 2
Ms. Wang, 52 years old, had suffered from vitiligo for more than six years, with widespread depigmentation lesions on the chest, neck and jaw, and an irregular connection between the chest and neck. Various treatments were attempted during this period, but none were effective, leading her to experience a period of depression. She received TB-39 immunization in May 2018. After the fourth immunization (September 2018), it was observed that the white spots on her jaw had mostly disappeared, while the depigmented areas on her chest and neck had significantly reduced, bringing her skin color closer to normal. Follow-up evaluation over nearly 2 years showed no recurrence or aggravation of her condition.
TK-129 Case Study 3
The patient was diagnosed with vitiligo many years ago. After immunization with heat shock protein gp96, the white spots on his hands have nearly disappeared, and his skin color has returned to near normal.
Comparison before and after immunization:
TK-129 Case Study 4
The patient was diagnosed with psoriasis several years ago. During this period, he tried various treatments, but his condition repeatedly recurred without improvement. He received TB-39 immunization in May 2019, completing a total of eight sessions. After the second immunization, a follow-up examination in June 2019 showed slight improvement in the thickness and area of the larger skin lesions on both lower limbs. He continued with the immunization regimen. After the eighth immunization, his condition gradually stabilized. The skin lesions on both lower limbs shrank significantly, and his skin color approached to normal. The results of the follow-up after 15 months are as follows:
Comparison before and after immunization
TK-129 Case Study 5
The patient was diagnosed with psoriasis several years ago. During this period, he tried various treatments, but his condition kept recurring without improvement. In June 2022, he received TB-39 immunization for a total of three sessions. His condition is currently stable, with the skin on his back having shrunk and his skin color nearing normal.
Comparison before and after immunization
TK-129 Case Study 6
On November 17, 2023, the patient developed symptoms and was diagnosed with allergic purpura three days later. Subsequently, symptoms such as abdominal pain, diarrhea, and joint pain appeared. Hormone control was ineffective.
On December 29, 2023, TB-39 vaccination was initiated, with a total of three sessions administrated. Hormone treatment has been discontinued, and the skin on both feet has returned to normal.
Comparison before and after immunization
TK-129 Case Study 6
Ms. Zhang, 32 years old, has been living with systemic lupus erythematosus for more than 20 years, during which she underwent hormone maintenance therapy, maintaining stable health. In October 2016, she developed anemia due to dysfunctional uterine bleeding, which exacerbated her condition. Treatment with TB-39 immunization began in December of the same year.
After the fifth immunization, a re-examination revealed d that her urine protein was 1+, urine occult blood turned negative, and her hemoglobin was 10.3G. Consequently, her hormone dosage was reduced from 2-4 tablets to 1 tablet. After one year of follow-up, her condition remained stable.
By 2018, her hemoglobin and urine protein levels had returned to normal, and her hormone dosage was further reduced to 3/4 tablets. In order to consolidate the therapeutic effect, it was recommended that she reveive immunization once every three months. Recent reexaminations have shown her condition to be stable, and her hormone dosage has been decreased to 1/2 tablet.
Comparison before and after immunization
Hyperlipidemia and Treatment Methods
Introduction to the dangers of hyperlipidemia and its treatment
Dangers of hyperlipidemia
Hyperlipidemia leads to systemic arteriosclerosis, affecting the entire body, and potentially causing l fatal diseases.
Hyperlipidemia treatment methods
Blood Separation Technology
—Leading technology with safe applications, certified by the world’s three major certification systems!
Widely used and highly acclaimed by medical institutions worldwide!
Lipid removal therapy for acute cerebral infarction –
Significant reduction in blood viscosity
High Efficiency Physical Blood lipid Separation Removal
Before and after efficient physical lipid fractionation
Lipid-lowering:
Data from the overview and clinical validation summary of in vitro lipid apheresis technology indicate that a total of 300
cases met the following inclusion criteria:
(1) Age 18~65 years, with no gender restriction.
(2) Total cholesterol (TC) ≥ 5.72mmol/L, or low-density lipoprotein (LDL) ≥3.64mmol/L, or triglyceride (TG) ≥2.2mmol/L,
or blood viscosity above normal levels.
(3) Patients who cannot tolerate lipid-lowering drug therapy due to conditions such as liver damage or rhabdomyolysis.
Plasma adsorption
Plasma adsorption involves drawing blood, which first enters the plasma separator to separate the formed elements of
the blood (blood cells and platelets) from plasma. The formed elements are then transfused back into the patient’s body,
while the plasma proceeds to the adsorber. In the absorber, specific substances are removed from the plasma, before the
treated plasma is returned to the patient’s body.
